Neovacs to Expand Clinical Testing of its TNF-a Kinoid Lead Product Candidate
News Jun 29, 2009
Neovacs has announced that subject to regulatory consent, it plans to initiate a Phase II study of its TNF-a Kinoid later this year in rheumatoid arthritis patients who have failed treatment with at least one TNF-a inhibitor.
The decision to proceed with the trial was based on an initial review of encouraging data from the company’s Phase I/II study in Crohn’s disease.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE